RE:RE:RE:RE:RE:RE:RE:RE:Swapan Kakumanu
They had about 5.5 million left as of 31 July. That was before the 750k to the genomics company. Total expenses in the three months up to 31 July of 9 million, including listing cost, stock compensation, and corporate development. Hopefully most of the big costs are out of the way and the 5.5 can sail through to when revenues start coming in.